Global pharma major Venus Remedies has received its second patent grant from the Australian Patent office (APO) for Vancoplus,an antibiotic drug to combat Methicillin Resistant Staphylococcus Aureus or MRSA infections.
The company had earlier won a patent grant from the Australian Government for Potentox which is valid until February 2026.
With Vancoplus,Venus expects to grab a fair share of the $9 billion MRSA market,within 3 years. As Antimicrobial Resistance is a growing concern globally,getting this patent grant from Australia for our Antimicrobial Resistance product Vancoplus is a milestone in the war against Microbial resistance, said Manu Chaudhary,joint managing director and director-research,Venus Remedies Ltd,in a statement to the media.
Vancoplus is a cost effective product and acts as a remedy for MRSA,VRSA (Vancomycin Resistance Staphylococcus aureus) and multi-drug resistant bacteria which causes ailments such as meningitis,pneumonia,typhoid,septicemia,urinary tract infection,skin and skin infections and staphylococcal endocarditis. It also said reduces treatment time for these diseases.
The product has already received patent grants from USA,Japan,South Africa,New Zealand and Ukraine. Such grants for from Canada,Europe,Brazil,Mexico and India yet to be granted.